When government drug development incentives and free enterprise result in exorbitant price hikes, it is typically patients, not stockholders, who are caught in the crosshairs. When the drug in question is unique in its ability to treat infants with a potentially life-threatening seizure disorder, boosting the price by 1,400% overnight seems indelicate at best. Yet that is exactly what Questcor Pharmaceuticals did in August 2007 when it increased the price of H.P. Acthar Gel (ACTH) from $1,600 to $23,000 USD per vial…
Filed under: NerveCenter | Tagged: Acthar, Questcor, Pharmaceutical, price gouging, infantile spasm, orphan drug, orphan disease, rare disease, seizure, Senator Charles Schumer, Senator Amy Klobuchar, ACTH, FDA, Pharmaceutical Research and Manufacturers of America, PhRMA, Partnership for Prescription Assistance, viagra, research and development cost | 3 Comments »
